Wells Fargo & Company Pax Medica, Inc. Transaction History

Wells Fargo & Company

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.76 - $2.08 $9 - $24	12 Added 52.17%	35 $0
Q1 2023 May 12, 2023	BUY	$1.42 - $3.62 $1 - $3	1 Added 4.55%	23 $0
Q4 2022 Feb 13, 2023	BUY	$1.4 - $53.55 $30 - $1,178	22 New	22 $0

Ticker PXMD
Exchange
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,779,500
Market Cap $1.06M
Description
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, my...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.